(subsequently referred to as Hain V1), which was endorsed by WHO in 2008. This assay includes rpoB probes to determine RIF resistance, katG probes to determine high-level INH resistance, and inhA probes (not included in the initial GenoType® MTBDR assay) to determine low-level INH resistance. Hain developed an updated version of the MTBDRplus line probe assay in 2011 (subsequently referred to as Hain V2) to replace Hain V1. Hain V2 has an improved sample preparation that showed increased sensitivity for TB detection in the 2 studies published so far. Hain 
kansasii.
The rpoB, katG and inhA mutation probes are the same for the three assays aside from the katG S315N mutation, which is included in the Nipro assay but not Hain V1/V2. In addition there are some minor variations in the codon regions covered for the wild type between Hain V1/V2 and Nipro (see The composite reference standard took into account the results from phenotypic DST and sequencing. If results were discrepant between phenotypic DST and sequencing, the final determination was based on whether the sequencing mutations detected are thought to be clinically significant (i.e. associated with resistance) using the TB dream database as a reference [22] and ReSeqTB (David Dolinger, personal communication) and additional clinical outcomes data [23] . The composite reference standard was constructed without knowledge of LPA results. If conventional DST showed sensitivity but sequencing identified mutations recognized to be associated with resistance, the composite reference standard was considered resistant. If conventional DST shows resistance but sequencing does not identify mutations to be associated with resistance, the composite reference standard was considered resistant (as mutations will be assumed outside of the region sequenced or alternatively there may be low-level heteroresistance below the limit of detection of the some sequencing technologies used; e.g. Sanger). The composite reference standard was constructed without knowledge of LPA results.
Indeterminate or invalid results
Test results were defined as 'indeterminate' if test results were valid but readers were unable to draw conclusions on the presence or absence of RIF/INH-resistance based on the visible banding pattern.
This may be due to weak or completely absent bands for RIF or INH for a sample that tested positive for MTB on the LPA. Per manufacturers' instructions, test results were regarded invalid if either the conjugate/colour control or the amplification control was negative. Of note, the only exception is that if the LPA result is positive for MTB, the amplification control may be weak or negative due to competition of the amplification reaction and thus this constitutes a valid test result. Since studies often do not differentiate between indeterminate and invalid results, we reported them together and described these as indeterminate. Risk of Bias was scored as 'low risk' if selection was done in a random or consecutive manner, avoided a case-control design and there were no inappropriate exclusions. Risk of Bias was scored as 'high risk' if selection was by convenience or based on a case-control design; and 'unclear risk' if the manner of participant selection was unclear or information on patient or specimen selection was not provided.
Applicability: Are there concerns that the included patients and setting do not match the review question?
We are interested in how LPA performed in patients suspected of having PTB who were evaluated as they would be in settings of intended use, based on the description of the clinical and laboratory settings in which the test was evaluated. Per current guidelines, LPA should be performed in laboratories at the district level and above. If study setting was below the district level, this raised the concern that the included patients and setting did not match the review question, given the infrastructure and quality control measures needed for a laboratory to perform LPA testing. We judged 'low' concern if the selected specimens match the review question, which reflects the way the test will be used in practice. We judged 'high' concern if the selected specimens or isolates did not represent those for which the test will be used in practice, such as extrapulmonary samples. We judged 'unclear' concern if we cannot tell.
Domain 2: Index Test

Risk of Bias: Could the conduct or interpretation of the index test have introduced bias?
 Signaling question 1: Were the index test results interpreted without knowledge of the results of the reference standard? We will score 'yes' if the resistance pattern of the specimen for LPA testing was interpreted without knowledge of the reference standard. We scored 'no' for all studies where LPA was performed without blinding to the results of reference specimens (blinding was more likely for fresh rather than frozen specimens). It is possible that bias could have be introduced when LPA is performed on culture specimens since interpretation of the test requires subjective analysis of the pattern of strips detected. If the index test is interpreted with an automated reader there should be no bias, however if it is hand interpreted or if the reader can be modified, this is subjective and could introduce bias. End users should be provided with a printed result that is not subject to interpretation. Wescored 'unclear' if this is not stated.  Signaling question 2: If a threshold was used, was it prespecified? The threshold was prespecified in all versions of LPA i.e. we score 'yes' for all studies.
For risk of bias, we judged 'low risk' for studies that were blinded or where LPA was clearly performed and recorded prior to culture results being available, 'high risk' for unblinded studies, and 'unclear risk' for studies where blinding status was unclear or unspecified. Although sample processing was likely to be different between studies, this is unlikely to introduce systematic bias. For risk of bias, we judged 'low risk' if the reference standard used is WHO-endorsed and performed as per WHO recommendations or if a composite reference standard was used and if the reference standard was interpreted without knowledge of the index LPA result. We judged 'high risk' if the reference standard was interpreted with knowledge of the index LPA test and 'unclear risk' if the standards under which the reference standard were performed were unclear.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question?
We judge applicability to be of 'low concern' for all studies.
Domain 4: Flow and Timing
Risk of Bias: Could the patient flow have introduced bias?
 Signaling question 1: Was there an appropriate interval between the index test and reference standard? We scored 'yes' if the tests were paired or separated by less than 48 hours after treatment initiation. We scored 'no' if the reference and index tests were not performed on paired samples or were separated by more than a week. We scored 'unclear' if this was not stated in the paper or answered inadequately. In the majority of included studies, we expected specimens for LPA and culture to be obtained at the same time (i.e. to be performed on paired samples for the majority of studies), when patients are suspected of having TB or MDR-TB. Although TB is often a chronic infection thus making misclassification of disease status unlikely, being on treatment could alter the microbial population of specimens collected more than 48 hours after treatment initiation.
 Signaling question 2: Did all patients receive the same reference standard? We scored 'yes' if all studies used the same reference standard (acceptable reference standard as specified above, i.e. either phenotypic, genotypic or composite reference standard, as a criterion for inclusion in the review). We scored 'no' if different reference standards were used or if the reference standard was only applied to a selective group of patients or if culture was followed by sequencing of only the discrepant results because this could introduce potential verification bias if the same reference standard was not used to confirm all index test results. We scored 'unclear' if this was not stated in the paper or answered inadequately.
 Signaling question 3: Were all patients included in the analysis? The answer to this question was determined by comparing the number of patients enrolled with the number of patients included in the two-by-two tables. We noted if authors recorded the number of indeterminate results. We scored 'yes' if the number of participants enrolled was clearly stated and corresponded to the number presented in the analysis or if exclusions were adequately described. We scored 'no' if there were participants missing or excluded from the analysis and there was no explanation given; and 'unclear ' if not enough information was given to assess whether participants were excluded from the analysis e.g. if the number of participants originally enrolled in the study was not explicitly stated.
For risk of bias, we judged 'low risk' if the index and reference tests were performed on paired specimens or performed within less than 48 hours of treatment, if the same reference standard was applied to all patients or specimens and if all patients or specimens were included. We judged 'high risk' if the interval between the index and reference test was >48 hours after treatment initiation or if different reference standards were applied to different groups included in the study or if patients or specimens were inappropriately excluded. We judged 'unclear risk' if the interval between reference and index tests was unclear or if it was unclear that the same reference standard was not applied to all participants or specimens or if it is unclear whether patients or specimens were excluded from the analysis inappropriately.
Appendix D2. Characteristics related to Methodological Quality (QUADAS-2) for included studies.
Patient Selection
Rifampicin Resistance 17 datasets were judged to have a 'high risk of bias'. In 2 datasets, this was due to the lack of consecutive or random sampling of patients or specimens and in 14 datasets this was due to the use of a case-control design. 21 datasets were judged to have a 'low risk of bias'. In 56 datasets, the risk of bias was 'unclear'. In 54 of these 56 datasets, the method of sampling patients or specimens was not specified, 1 dataset had an unclear design and in 1 dataset it was unclear whether there had been inappropriate exclusions. In 15 of these 54 datasets with an unclear method of sampling, the design of the study was also unclear. In 1 of these 54 datasets, it was also unclear whether there had been inappropriate exclusions. Applicability in this domain focused on whether the patients who underwent LPA testing and whether the clinical and or laboratory settings were appropriate for their intended use. Applicability was judged to be 'low-risk' in 76 datasets and no datasets were 'high-risk'.
18 datasets were judged to be of 'unclear-risk', 10 of which did not specify the type of patients or specimens that were tested, 7 of which did not specify the laboratory setting in which testing was performed and 1 of which did not specify either of these factors.
Isoniazid resistance detection
In the 'patient selection' domain, 16 datasets were judged to have a 'high risk of bias'. In 2 datasets, this was due to the lack of consecutive or random sampling of patients or specimens and in 13 datasets this was due to the use of a case-control design. 21 datasets were judged to have a 'low risk of bias'. In 53 studies, the risk of bias was 'unclear'. In 50 of these 53 datasets, the method of sampling patients or specimens was not specified and in 1 dataset it was unclear whether there had been inappropriate exclusions. In 14 of these 50 datasets with an unclear method of sampling, the design of the dataset was also unclear. In 1 of these 50 datasets, it was also unclear whether there had been inappropriate exclusions. Applicability in this domain focused on whether the patients who underwent LPA testing and whether the clinical and or laboratory settings were appropriate for their intended use. Applicability was judged to be 'low-risk' in 72 datasets and no datasets were 'high-risk'.
MTB detection
In the 'patient selection' domain, 5 datasets were judged to have an 'unclear risk of bias' because the method of sampling patients or specimens was not specified and the other dataset had a 'low risk of bias'. Applicability in this domain focused on whether the patients who underwent LPA testing for MTB detection and whether the clinical and or laboratory settings were appropriate for their intended use. Applicability was judged to be 'low-risk' in 5 datasets and no datasets were 'high-risk'. 1 dataset was judged to be of 'unclear-risk' as the laboratory setting in which testing was performed was not specified.
Index Test
Rifampicin Resistance
In the 'index test' domain, 0 datasets were judged to have a 'high risk of bias'. 28 datasets were judged to have a 'low risk of bias'. In 66 datasets, the risk of bias was 'unclear', because datasets did not specify whether the person performing the index test was blinded to the results of the reference standard testing. Applicability in this domain focused on whether the conduct of performing and interpreting the index test was in line with the manufacturer's recommendations. Applicability was judged to be 'low-risk' in 86 datasets. 8 datasets were judged to 'high-risk' for applicability concerns due to variations in which the test was performed that were not according to the manufacturer's recommendations.
Isoniazid resistance detection
In the 'index test' domain, 0 datasets were judged to have a 'high risk of bias'. 27 datasets were judged to have a 'low risk of bias'. In 63 datasets, the risk of bias was 'unclear', because datasets did not specify whether the person performing the index test was blinded to the results of the reference standard testing. Applicability in this domain focused on whether the conduct of performing and interpreting the index test was in line with the manufacturer's recommendations. Applicability was judged to be 'low-risk' in 82 datasets. 8 datasets were judged to 'high-risk' for applicability concerns due to variations in which the test was performed that were not according to the manufacturer's recommendations.
MTB detection
In the 'index test' domain, 0 datasets were judged to have a 'high risk of bias'. 4 datasets were judged to have a 'low risk of bias'. In 2 datasets, the risk of bias was 'unclear', because datasets did not specify whether the person performing the index test was blinded to the results of the reference standard testing. Applicability in this domain focused on whether the conduct of performing and interpreting the index test was in line with the manufacturer's recommendations. Applicability was judged to be 'low-risk' in 5 datasets. 1 dataset was judged to be 'high-risk' for applicability concerns due to a variation in which the test was performed that were not according to the manufacturer's recommendations.
Reference Standard
In the 'reference standard' domain, 0 datasets were judged to have a 'high risk of bias'. 26 datasets were judged to have a 'low risk of bias'. In 68 datasets, the risk of bias was 'unclear', because datasets did not specify whether the person performing the reference test was blinded to the results of the index test. Applicability in this domain focused on whether the conduct of performing and interpreting the index test was in line with the manufacturer's recommendations. Applicability was judged to be of 'low-concern' in all 94 datasets.
Isoniazid resistance detection
In the 'reference standard' domain, 0 datasets were judged to have a 'high risk of bias'. 25 datasets were judged to have a 'low risk of bias'. In 65 datasets, the risk of bias was 'unclear', because datasets did not specify whether the person performing the reference test was blinded to the results of the index test. Applicability in this domain focused on whether the conduct of performing and interpreting the index test was in line with the manufacturer's recommendations. Applicability was judged to be of 'low-concern' in all 90 datasets.
MTB detection
In the 'reference standard' domain, 0 datasets were judged to have a 'high risk of bias'. 3 datasets were judged to have a 'low risk of bias' and 3 datasets were judged to have an 'unclear risk of bias'
as they did not specify whether the person performing the reference test was blinded to the results of the index test. Applicability in this domain focused on whether the conduct of performing and interpreting the index test was in line with the manufacturer's recommendations. Applicability was judged to be of 'low-concern' in all 6 datasets.
Flow and Timing
Rifampicin Resistance
In the 'flow and timing domain, 12 datasets were judged to have a 'high risk of bias' because more than one type of reference standard was used and not all patients or specimens received the same reference standard. 78 datasets were judged to have a 'low risk of bias'. In the remaining 4 datasets, the risk of bias was 'unclear', because 3 datasets did not specify the type of reference standard that was used and 1 dataset did not include all patients in the 2x2 tables.
Isoniazid Resistance
In the 'flow and timing domain, 12 datasets were judged to have a 'high risk of bias' because more than one type of reference standard was used and not all patients or specimens received the same reference standard. 74 datasets were judged to have a 'low risk of bias'. In the remaining 4 datasets, the risk of bias was 'unclear', because 3 datasets did not specify the type of reference standard that was used and 1 dataset did not include all patients in the 2x2 tables.
MTB Detection
In the 'flow and timing domain, all 6 datasets were judged to have a 'low risk of bias'. 
Appendix D3. Risk of bias and applicability summaries for each QUADAS-2 domain by study
Unable to translate
Thirteen studies used different populations of patients or specimens to perform indirect and direct testing separately and were thus included as two separate datasets [19, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Only one of these studies performed head-to-head testing of all three target LPAs on directly tested clinical specimens and indirectly tested isolates and was included as 6 separate datasets [19] . One study performed indirect testing on two different populations with two different phenotypic reference standards and was included as two separate data sets [41] . Two studies (excluded from MTB analysis due to patient treatment history) examined two different populations of TB patients and were included as four separate datasets. One of these studies recruited 'chronic' TB patients failing first line therapies and had two populations: one enrolled prior to starting second line treatment and one population who were enrolled within the first month of treatment [42] . The second study enrolled patients with no prior history of TB and tested them at the beginning of treatment and then again in the 5 th month of treatment [43] . Of the total 94 unique datasets, 74 (79%) evaluated patients from low-or middleincome countries. In 57 (61%) datasets, the laboratory setting where LPA was performed was in a low-or middle-income country. Figure S5 . Forest plots demonstrating sensitivity and specificity of all the LPAs evaluated for the diagnosis of rifampicin resistance compared against a composite reference standard for all samples regardless of specimen type. Figure S6 . Forest plots demonstrating the sensitivity and specificity of all the LPAs evaluated for the diagnosis of isoniazid resistance for culture isolates that were tested indirectly against phenotypic DST. Figure S7 . Forest plots demonstrating the sensitivity and specificity of all the LPAs evaluated for the diagnosis of isoniazid resistance compared against a composite reference standard for all samples regardless of specimen type. Figure S8 . HSROC graphs of summary estimates for all specimens for RIF and INH resistance (indirect) Bivariate analysis of the sensitivity and specificity for all LPAs for the diagnosis of drug resistance compared to a phenotypic reference standard in specimens tested indirectly for a) RIF resistance b) INH resistance. In the plots below, the red squares represent the pooled summary estimates, the dashed red lines represent the 95% confidence region and the dashed green lines represent the 95% prediction region. The individual circles represent each study and the size of the circle is proportional to the total sample size. a) b)
